Kalaris Therapeutics Inc (KLRS) Stock

Kalaris Therapeutics Inc (KLRS) is a Healthcare stock trading at $4.69 (as of 2026-06-18), with a market capitalization of $125.39M and a trailing P/E of -6.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Valuation — source: SEC EDGAR (first-party)
Price$4.69
Market Cap$125.39M
P/E Ratio-6.0
EV / EBITDA-1.6
Price / Book1.64
Price / Sales20.47
DCF Value (model)$-24.34
DCF Upside vs Price-619.0%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$5.49M
Net Margin-1071.3%
Return on Equity-64.3%
Current Ratio12.19
Revenue Growth (YoY)-4.3%
EPS Growth (YoY)541.0%
Valuation vs Sector & Industry
Stock P/E-6.0
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-128.6%
vs Industry-135.1%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderSAMSARA BIOCAPITAL, LLC ($74.71M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOAndrew Oxtoby
Employees14
CountryUS
IPO Date2020-07-30

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Organigram Global Inc. (OGI)
  • Nuvectis Pharma, Inc. (NVCT)
  • Cardiff Oncology, Inc. (CRDF)
  • Sagimet Biosciences Inc. (SGMT)
  • Climb Bio, Inc. (CLYM)
  • Journey Medical Corporation (DERM)
  • Cartesian Therapeutics, Inc. (RNAC)
  • Quince Therapeutics, Inc. (QNCX)
KLRS earnings history · KLRS institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.